At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
LY2409021 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of LY2409021 in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating LY2409021 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 87 participants across 19 sites in 3 countries.
Detailed Summary
This drug is being evaluated for possible treatment of type 2 diabetes mellitus. Participation in this study is expected to last up to 18 weeks. A goal of this study is to determine the safety and effectiveness of LY2409021.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany, Lithuania, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMar 2009
Primary CompletionFeb 2010
TodayJul 2026
First PostedMar 30, 2009
Enrollment StartMar 1, 2009
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.3 years ago
Interventions
LY2409021drug
4 capsules by mouth taken once daily for 12 weeks
Placebodrug
4 capsules by mouth once daily for 12 weeks